Riluzole neuroprotection in a parkinson’s disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.

View/ Open
art_Riluzole_10.1186_1471-2202-13-38.pdf (439.2Kb)
Download
Publication date
2012-04Keyword
Riluzole, EAAT2, GLT-1, Neuroprotection, Parkinson’s Disease, GFAP, Glial cell, 6-hydroxydopamineRights
© 2012 Carbone et al. Published Open Access by BioMed Central. Reproduced in accordance with the publisher's self-archiving policy.Peer-Reviewed
yes